A pharmacokinetic study of dalteparin (Fragmin®) during late pregnancy

Seventeen women with previously verified thromboembolism were included in a pharmacokinetic evaluation of dalteparin during the third trimester of pregnancy. The bioavailabilityof morningsubcutaneous administration of dalteparin ( crossover study) was also compared with that in the evening. Fifteen